Catalent Pharma Solutions has increased its minority investment in Redwood Bioscience, which has site-specific protein modification and linker technologies through a proprietary platform (SMARTag) used to generate homogeneous antibody-drug conjugates.

Catalent announced in April 2013 that it had acquired an exclusive license to market the SMARTag technology and has subsequently collaborated with Redwood for the ongoing development and marketing of the technology. As part of the collaboration, Catalent took a minority equity stake in Redwood, which may increase over time up to a potential acquisition.

Source: Catalent Pharma Solutions